Acquisition Strengthens Illumina’s Clinical Readiness
SAN DIEGO--(BUSINESS WIRE)--Jul. 16, 2014--
Illumina, Inc. (NASDAQ:ILMN) today announced that it has acquired
Myraqa, a regulatory and quality consulting firm specializing in IVDs,
particularly companion diagnostics. Led by founder and CEO Mya Thomae,
Myraqa focuses on regulatory strategy and application support, including
PMAs, pre-submissions, IDEs, 510(k)s, de novo 510(k)s, and EU technical
files. The acquisition will bolster Illumina’s in-house capabilities for
clinical readiness and help prepare for its next growth phase in
“Under Mya Thomae, Myraqa is recognized as the leader in regulatory and
quality matters in molecular diagnostics,” said Rick Klausner, M.D.,
Chief Medical Officer of Illumina. “With Myraqa, Illumina will continue
to pave the way for the use of genomic technology, including
next-generation sequencing, in regulated markets while also driving
standards for use in the clinic. Mya will lead Illumina’s regulatory
strategy and execution, providing us with a world-class regulatory
organization and is part of our commitment to making Illumina a
pre-eminent clinical company.”
“Illumina is at the forefront of driving next-generation sequencing to
the clinic and I look forward to being a key part of this market
transformation,” said Mya Thomae, CEO of Myraqa. “Illumina exemplifies
many of the values that have successfully guided Myraqa and I’m excited
for our team to share in this opportunity to shape the future of
As part of Illumina, Myraqa’s team will continue to report to Thomae.
Thomae will report to Illumina’s CMO Dr. Klausner as the Vice President
of Regulatory Affairs.
“We expect Mya and her team to complete existing programs and to
continue to work with selected third-parties on sequencing-based
projects,” added Dr. Klausner.
Myraqa is based in Redwood Shores, California and was founded in 1998.
It comprises leading experts in regulatory, quality, clinical,
biostatistics and development.
The financial impact of this transaction was contemplated in the 2014
financial guidance released on April 22, 2014.
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks
and uncertainties. Important factors that could cause actual results to
differ materially from those in any forward-looking statements are
detailed in our filings with the Securities and Exchange Commission,
including our most recent filings on Forms 10-K and 10-Q, or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.
Source: Illumina, Inc.